Drug Profile
AE 07
Alternative Names: AE07Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Aetas Pharma
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Shock
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for research development in Cardiovascular-disorders in Japan
- 28 Sep 2021 No recent reports of development identified for research development in Shock in Japan
- 03 Aug 2017 Early research in Cardiovascular disorders in Japan before August 2017 (Aetas Pharma pipeline, August 2017)